New Protein Sequencing Tech Reveals Cancer's Molecular Secrets

BRANFORD, Conn. – April 14, 2026 – A groundbreaking study from Canadian researchers has provided a rare, molecular-level glimpse into a protein malfunction central to cancer development, a discovery made possible by next-generation protein sequencing technology from Quantum-Si. The findings, detailed in a new pre-print manuscript, not only solve a complex biological puzzle but also illuminate a potential new path for developing targeted cancer therapies.

The research, conducted at the University of British Columbia and the B.C. Cancer Research Institute, focused on a critical protein machine known as cohesin. By using Quantum-Si's single-molecule analysis platform, the scientists were able to observe a phenomenon that had eluded conventional detection methods, providing a powerful validation for the emerging field of high-resolution proteomics.

The Cohesin Conundrum: A Key to Genomic Instability

At the heart of every living cell, the cohesin complex acts as a master organizer and guardian of the genome. This intricate, ring-shaped protein structure is essential for life, performing the critical task of holding sister chromatids together during cell division to ensure each new cell receives a perfect copy of the genetic blueprint. Its role, however, extends far beyond cell division, also influencing DNA repair and the three-dimensional folding of DNA that controls which genes are switched on or off.

Given its fundamental role, it is no surprise that when cohesin malfunctions, the consequences can be catastrophic. Mutations in cohesin genes are frequently found in a wide array of human cancers, including bladder cancer, glioblastoma, and certain leukemias. These defects can lead to genomic instability—a chaotic state of chromosome abnormalities and DNA damage that is a defining hallmark of cancer. This connection has made the cohesin complex a significant area of interest for oncologists and drug developers seeking to find and exploit cancer's unique vulnerabilities.

In their innovative study, the researchers engineered yeast cells to produce human cohesin proteins alongside the yeast's native version. They hypothesized that the foreign human proteins would interfere with the normal function of the yeast's own cohesin machinery. The results were dramatic: the yeast cells exhibited a "dominant-negative" effect, displaying classic cancer-related symptoms like an inability to properly replicate their DNA, heightened sensitivity to DNA damage, and a stall in the cell cycle. While these effects pointed to a disruption, the precise molecular mechanism remained hidden.

A Technological Leap in Protein Analysis

Identifying exactly how the human cohesin was sabotaging the yeast's cellular machinery presented a significant technical challenge. Traditional methods, such as antibody-based assays like Western blots, can confirm the presence of proteins but often lack the precision to distinguish between highly similar proteins or detail their direct interactions within a complex. Even advanced mass spectrometry, a powerful tool for identifying proteins in a sample, struggled to provide a definitive answer. The central question was whether the human and yeast cohesin proteins were physically assembling into dysfunctional hybrid complexes.

This is where Quantum-Si's technology provided the crucial breakthrough. The company's benchtop platform performs single-molecule protein sequencing, a method that analyzes individual protein molecules one by one. This provides direct, unbiased, and sequence-level data that bypasses the limitations of older, bulk-analysis techniques. By pulling down the human cohesin from the engineered yeast cells and analyzing the associated proteins molecule by molecule, the researchers obtained irrefutable proof.

The platform identified individual protein strands, reading their amino acid sequences in real-time. The data clearly showed that yeast cohesin proteins were physically bound to the human cohesin proteins, forming the suspected hybrid complexes. This sequence-level evidence was the "smoking gun" that confirmed the molecular basis for the dominant-negative effect. It was a first-of-its-kind observation that demonstrated the platform's power to resolve complex biological questions that were previously unanswerable.

Paving the Way for Novel Therapeutic Strategies

The study's implications extend far beyond the laboratory bench. By confirming the mechanism of cohesin interference, the research opens a new frontier for therapeutic development. The "dominant-negative" effect observed in yeast could potentially be exploited as a strategy to selectively target cancer cells that already have existing cohesin mutations. This approach, known as synthetic lethality, is a cornerstone of modern precision oncology. It involves finding a drug or intervention that is harmless to normal cells but lethal to cancer cells due to a specific pre-existing mutation.

By understanding how to disrupt cohesin function, researchers may be able to design therapies that push cohesin-mutant cancer cells over the edge, causing them to self-destruct while leaving healthy cells unharmed. This represents a more elegant and targeted approach to cancer treatment, moving away from the slash-and-burn tactics of traditional chemotherapy.

"In this study, single‑molecule protein sequencing enabled the researchers at University of British Columbia and B.C. Cancer Research Institute to directly identify hybrid cohesin complexes, demonstrating the value of our technology as a foundational tool for mechanistic biology research and therapeutic discovery," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si, in a statement. The findings underscore how foundational tools that provide deeper mechanistic insights can directly accelerate the path toward new medicines.

A Critical Validation in the Competitive Proteomics Market

For Quantum-Si, the manuscript represents a landmark achievement. As the first peer-reviewed publication from independent, international researchers using its platform, it serves as a powerful external validation of the technology's capabilities and scientific value. In the highly competitive proteomics market, where companies vie to provide researchers with the most powerful tools for protein analysis, such proof-of-performance is critical.

This validation helps shift the narrative for the company from one of technological promise to one of demonstrated scientific impact. The ability to uncover novel biology relevant to actionable cancer pathways strengthens Quantum-Si's position as a key player in the next generation of life sciences tools. This success is likely to resonate with investors and may accelerate the broader adoption of its platform in academic and pharmaceutical research labs worldwide. As researchers continue to tackle increasingly complex diseases, the demand for tools that can deliver unambiguous, single-molecule resolution is only set to grow, placing technologies like Quantum-Si's at the forefront of future biological discovery.